Cape Town, 22 July-(ANA)-An AIDS prevention trial, evaluating both a microbicide and oral tablets in one study, starts soon in Zimbabwe as researchers seek to reduce the disease burden among women.
About 5,000 sexually active women are expected to enroll at sites in Zimbabwe, South Africa, Uganda, Zambia and possibly Malawi as part of the study, conducted by the U.S-funded Microbicide Trials Network.
The study will determine whether some of the antiretroviral (ARV) medicines used to treat HIV can also be used to prevent the disease when given as a vaginal microbicide gel or as an oral tablet taken once daily.
In addition, the study, which will specifically test the ARV tablets tenofovir and Truvada, seeks to find out which of the two approaches women would prefer. Tenofovir was also the active ingredient in the vaginal gel.(ANA)
Google/Staff Protest